Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Obesity · Type 2 diabetes

NovoThirteen

NovoThirteen trial registry — 94 ClinicalTrials.gov studies with program phase, status, and indication context.

Bagsværd, JP HQ
PMDA registrant Type
Company details
Status
Public
HQ
Bagsværd, JP
Programs
94
Drugs
67
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

NovoThirteen clinical trials

Registry index of 94 ClinicalTrials.gov studies linked to NovoThirteen programs — each row shows trial ID, program name, phase, status, and indication.

NovoThirteen trial registry — 94 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for NovoThirteen.

  1. NN8022-4392 — Phase 3

    Clinical update

  2. NN7415-4311 — Phase 3

    Clinical update

  3. NN7415-4307 — Phase 3

    Clinical update

  4. NN9833-8421 — Phase 1

    Clinical update

  5. NN7442-8454 — Phase 1

    Clinical update

  6. NN7442-7582 — Phase 1

    Clinical update

  7. NN6537-7650 — Phase 1

    Clinical update

  8. NN6019-4958 — Phase 3

    Clinical update

Trial registry

94 studies
  15. 2023-506827-26-00

    NN9535-4352

    Phase 3 active small_molecule

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    CTIS ↗
  20. 2023-506876-28-00

    ziltivekimab, Ziltivekimab

    Phase 3 active small_molecule

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    CTIS ↗
  27. 2023-506927-27-00

    NN8640-4467

    Phase 3 active small_molecule

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    CTIS ↗
  59. 2024-517883-49-00

    The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    Phase 1 active other

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    CTIS ↗
  79. 2025-520490-38-00

    NN7442-8454

    Phase 1 active other

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.